A unicorn bags another $220M to fund its plans to upend the clinical trial process

The focus on decentralized trials amid the pandemic has led investors to make some big bets on companies promising to shake up the contract research space. Reify Health is the latest, coming away with $220 million to end what it calls the “sit and wait” period during trial enrollment.


Click to view original post